Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2022 · 10-Q
Revenue$1.80M$1.80M+135.3% vs Q3 2021 Net Income-$12.39M-$12.39MN/M vs Q3 2021 EPS Diluted-$1.42-$1.42N/M vs Q3 2021 Gross Profit$1,895,000+596.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,944,000N/M Free Cash Flowderived-$6,588,000N/M Margins · derivedGross margin105.3%+69.7 pt vs Q3 2021
Operating margin-377.1%+564.5 pt vs Q3 2021
Net margin-688.3%+313.1 pt vs Q3 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end